UCB Offers to Buy Schwarz Pharma
ePT--the Electronic Newsletter of Pharmaceutical Technology
UCB SA has offered EUR 4.4 billion ($5.64 billion) in cash and stocks to acquire Schwarz Pharma AG.
Frankfurt, Germany (Sept. 25)––UCB SA (Brussels, Belgium, www.ucb-group.com) has offered EUR 4.4 billion ($5.64 billion) in cash and stocks to acquire Schwarz Pharma AG (Monheim, Germany, www.schwarzpharma.com). If approved, the combined company will be called UCB and will be based in Brussels.
The UCB offer of EUR 50 per share ($64.09) in cash and 0.8735 UCB shares was accepted by the Schwarz family, which owns 60% of the stock. Schroders Investment Management Ltd. and Capital Research and Management, which combined hold nearly 8% of Schwarz’s stock, also agreed to the deal.
The deal would create a company with annual revenues of more than EUR 3 billion ($4.23 billion) and annual research and development spending of more than EUR 700 million (almost $1 billion).
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
